SEC Form 4 · accession 0000899243-18-007986

Arcus Biosciences, Inc. · RCUS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Mar 19, 2018

Accepted (ET)

Mar 19, 2018 · 5:26 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001724521

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Mar 19, 2018	C	505,050	—	A	505,050	I	By Kaneko Capital, LLC
Common Stock^F1,F2	Mar 19, 2018	C	252,524	—	A	252,524	I	By Kaneko Investments, LLC
Common Stock^F1,F2	Mar 19, 2018	C	33,818	—	A	96,948	I	By Trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series A Convertible Preferred Stock^F2	—	Mar 19, 2018	C	505,050	D	—	—	Common Stock	505,050	I
Series B Convertible Preferred Stock^F2	—	Mar 19, 2018	C	252,524	D	—	—	Common Stock	252,524	I
Series B Convertible Preferred Stock^F2	—	Mar 19, 2018	C	31,253	D	—	—	Common Stock	31,253	I
Series C Convertible Preferred Stock^F2	—	Mar 19, 2018	C	2,565	D	—	—	Common Stock	2,565	I

F1The total represents shares received upon conversion of shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock.
F2The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.Q